{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:14:33Z","timestamp":1759335273175,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s13318-021-00678-0","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T18:02:50Z","timestamp":1617040970000},"page":"395-404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Population Pharmacokinetics of Vixotrigine in Healthy Volunteers and Subjects with Trigeminal Neuralgia, Painful Lumbosacral Radiculopathy and Erythromelalgia"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0215-296X","authenticated-orcid":false,"given":"Himanshu","family":"Naik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Forrestal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Cleall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Bockbrader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunny","family":"Chapel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"issue":"3","key":"678_CR1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pain.2007.07.026","volume":"131","author":"TR Cummins","year":"2007","unstructured":"Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: implications for mechanisms of pain. Pain. 2007;131(3):243\u201357.","journal-title":"Pain"},{"key":"678_CR2","first-page":"CD03345","volume":"4","author":"V Challapalli","year":"2005","unstructured":"Challapalli V, Tremont-Lukats IW, McNicol ED, et al. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev. 2005;4:CD03345.","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"678_CR3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0304-3959(99)00154-2","volume":"83","author":"SH Sindrup","year":"1999","unstructured":"Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83(3):389\u2013400.","journal-title":"Pain"},{"key":"678_CR4","first-page":"1207","volume":"2009","author":"JM Zakrzewska","year":"2009","unstructured":"Zakrzewska JM, Linskey ME. Trigeminal neuralgia. BMJ. Clin Evid. 2009;2009:1207.","journal-title":"Clin Evid."},{"issue":"23","key":"678_CR5","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.2174\/1381612054865028","volume":"11","author":"E Kalso","year":"2005","unstructured":"Kalso E. Sodium channel blockers in neuropathic pain. Curr Pharm Des. 2005;11(23):3005\u201311. https:\/\/doi.org\/10.2174\/1381612054865028.","journal-title":"Curr Pharm Des"},{"key":"678_CR6","doi-asserted-by":"publisher","DOI":"10.1124\/molpharm.120.000079","author":"C Hinckley","year":"2020","unstructured":"Hinckley C, Hinckley CA, Kuryshev Y, Sers A, Barre A, Buisson B, Naik H, Hajos M. Characterization of vixotrigine, a broad-spectrum voltage-gated sodium channel inhibitor. Mol Pharmacol. 2020. https:\/\/doi.org\/10.1124\/molpharm.120.000079.","journal-title":"Mol Pharmacol"},{"key":"678_CR7","unstructured":"Tate S, Davis JB, Owen D, et al. CNV1014802 a novel potent state\u2010dependent sodium channel blocker with broad preclinical antihyperalgesic efficacy. Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience; 2011: Program 275.206\/LL272"},{"key":"678_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12935","author":"H Naik","year":"2020","unstructured":"Naik H, Steiner D, Versavel M, Palmer J, Fong R. Safety, tolerability, and pharmacokinetics of single and repeat doses of vixotrigine in healthy Volunteers. J Transl Sci. 2020. https:\/\/doi.org\/10.1111\/cts.12935.","journal-title":"J Transl Sci"},{"key":"678_CR9","unstructured":"Naik H, Versavel M, Zhao Y, Miao X, Dunbar J. Effect of itraconazole on the pharmacokinetics of the Nav1.7-specific sodium channel blocker BIIB074 in healthy subjects [poster P081]. Presented at the American College of Clinical Pharmacology (ACCP) Annual Meeting; 17\u201319 September, 2017; San Diego (CA))."},{"key":"678_CR10","unstructured":"Naik H, Versavel M, Dunbar J. Single and Multiple dose pharmacokinetics and safety of Vixotrigine in healthy Japanese and Caucasian volunteers [posterPII-079]. Presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 120th Annual Meeting; 13\u201316 March 2019; Washington DC."},{"issue":"1","key":"678_CR11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cpdd.739","volume":"9","author":"J Dunbar","year":"2020","unstructured":"Dunbar J, Versavel M, Zhao Y, Naik H. Evaluation of the pharmacokinetic interaction between the voltage- and use-dependent Nav1.7 channel blocker vixotrigine and carbamazepine in healthy volunteers. Clin Pharmacol Drug Dev. 2020;9(1):62\u201373.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"678_CR12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(17)30005-4","volume":"16","author":"JM Zakrzewska","year":"2017","unstructured":"Zakrzewska JM, Palmer J, Morisset V, et al. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol. 2017;16(4):291\u2013300.","journal-title":"Lancet Neurol."},{"issue":"S1","key":"678_CR13","first-page":"S46","volume":"103","author":"H Naik","year":"2018","unstructured":"Naik H, Dunbar J, Layton G, Palmer J, Versavel M. Evaluation of the pharmacokinetics and tolerability of BIIB074, a Nav1.7-selective sodium channel blocker in adult and elderly male and female volunteers. Clin Pharmacol Ther. 2018;103(S1):S46.","journal-title":"Clin Pharmacol Ther."},{"issue":"1","key":"678_CR14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/jcph.1298","volume":"59","author":"R Fong","year":"2019","unstructured":"Fong R, Ballow CH, Naik H, Steiner D, Palmer J, White WB. Effects of a state- and use-dependent Nav1.7 channel blocker on ambulatory blood pressure: a randomized, controlled crossover study. J Clin Pharmacol. 2019;59(1):90\u20137.","journal-title":"J Clin Pharmacol."},{"issue":"4","key":"678_CR15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1472-8206.1999.tb00001.x","volume":"13","author":"O Chassany","year":"1999","unstructured":"Chassany O, Duracinsky M. Ethics and clinical trial. Fundam Clin Pharmacol. 1999;13(4):437\u201344.","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"678_CR16","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.dmpk.2017.11.245","volume":"33","author":"C Woodward","year":"2018","unstructured":"Woodward C, Naik H, Versavel M, et al. Phase 1 study to evaluate the absorption, metabolism and excretion of the NAV1.7-selective sodium channel blocker BIIB074. Drug Metab Pharmacokinet. 2018;33(1):S74.","journal-title":"Drug Metab Pharmacokinet."},{"key":"678_CR17","volume-title":"Introduction to NONMEM 7","author":"NONMEM Users Guide","year":"2010","unstructured":"NONMEM Users Guide. Introduction to NONMEM 7. Ellicott City: ICON Development Solutions; 2010."},{"key":"678_CR18","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270003253624","volume":"43","author":"EI Ette","year":"2003","unstructured":"Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol. 2003;43:610\u201323.","journal-title":"J Clin Pharmacol."},{"key":"678_CR19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1011527125570","volume":"28","author":"U W\u00e4hlby","year":"2001","unstructured":"W\u00e4hlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28:231\u201352.","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"678_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/978-1-62703-050-2_16","volume":"929","author":"J Gabrielsson","year":"2012","unstructured":"Gabrielsson J, Weiner D. Non-compartmental analysis. Methods Mol Biol. 2012;929:377\u201389. https:\/\/doi.org\/10.1007\/978-1-62703-050-2_16.","journal-title":"Methods Mol Biol."},{"issue":"8","key":"678_CR21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/BF03261929","volume":"51","author":"I Mahmood","year":"2012","unstructured":"Mahmood I. Prediction of clearance and volume of distribution in the obese fron normal weight subjects: an allometric approach. Clin Pharmacokinet. 2012;51(8):527\u201342.","journal-title":"Clin Pharmacokinet"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00678-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-021-00678-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00678-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T20:36:15Z","timestamp":1620074175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-021-00678-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["678"],"URL":"https:\/\/doi.org\/10.1007\/s13318-021-00678-0","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2021,3,29]]},"assertion":[{"value":"29 March 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No specific funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"H.N., Y.Z., S.C. (Cleall) and F.F. are employees and shareholders of Biogen. S.C. (Chapel) and H.B. are employees of Ann Arbor Pharmacometrics Group and performed the analyses funded by Biogen. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the views or position of any of their employers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the study protocol was approved by the local ethical committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from each patient taking part to the study, in compliance with the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guideline.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during and\/or analyzed from various studies are not publicly available for confidentiality reasons.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Custom NONMEM and R codes used for model building, simulations and computation\/representation of VPC are not publicly available but are available from the corresponding author upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors were involved in planning, executing, data set generation, analysis interpretation and summarization of the analyses.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}